Alar Pharmaceuticals Statistics

Total Valuation

Alar Pharmaceuticals has a market cap or net worth of TWD 12.22 billion. The enterprise value is 9.78 billion.

Market Cap	12.22B
Enterprise Value	9.78B

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	Jun 5, 2024

Share Statistics

Alar Pharmaceuticals has 66.80 million shares outstanding. The number of shares has increased by 7.66% in one year.

Shares Outstanding	66.80M
Shares Change (YoY)	+7.66%
Shares Change (QoQ)	+3.64%
Owned by Insiders (%)	21.68%
Owned by Institutions (%)	5.05%
Float	40.14M

Valuation Ratios

The trailing PE ratio is 26.86 and the forward PE ratio is 234.62.

PE Ratio	26.86
Forward PE	234.62
PS Ratio	23.91
PB Ratio	4.92
P/FCF Ratio	48.75
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.42, with an EV/FCF ratio of 39.00.

EV / Earnings	23.41
EV / Sales	20.84
EV / EBITDA	25.42
EV / EBIT	25.66
EV / FCF	39.00

Financial Position

The company has a current ratio of 39.65, with a Debt / Equity ratio of 0.03.

Current Ratio	39.65
Quick Ratio	39.50
Debt / Equity	0.03
Debt / EBITDA	0.00
Debt / FCF	0.00
Interest Coverage	8,883.14

Financial Efficiency

Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 16.06%.

Return on Equity (ROE)	28.12%
Return on Assets (ROA)	14.83%
Return on Capital (ROIC)	16.06%
Revenue Per Employee	21.33M
Profits Per Employee	18.99M
Employee Count	22
Asset Turnover	0.29
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +30.25% in the last 52 weeks. The beta is 0.17, so Alar Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+30.25%
50-Day Moving Average	203.63
200-Day Moving Average	255.22
Relative Strength Index (RSI)	36.98
Average Volume (20 Days)	286,752

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Alar Pharmaceuticals had revenue of TWD 469.27 million and earned 417.67 million in profits. Earnings per share was 6.81.

Revenue	469.27M
Gross Profit	469.27M
Operating Income	381.98M
Pretax Income	442.89M
Net Income	417.67M
EBITDA	384.33M
EBIT	381.98M
Earnings Per Share (EPS)	6.81

Full Income Statement

Balance Sheet

The company has 2.45 billion in cash and 759,000 in debt, giving a net cash position of 2.45 billion or 36.62 per share.

Cash & Cash Equivalents	2.45B
Total Debt	759,000
Net Cash	2.45B
Net Cash Per Share	36.62
Equity (Book Value)	2.48B
Book Value Per Share	37.16
Working Capital	2.39B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 253.58 million and capital expenditures -2.84 million, giving a free cash flow of 250.74 million.

Operating Cash Flow	253.58M
Capital Expenditures	-2.84M
Free Cash Flow	250.74M
FCF Per Share	3.75

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 81.40% and 89.00%.

Gross Margin	100.00%
Operating Margin	81.40%
Pretax Margin	94.38%
Profit Margin	89.00%
EBITDA Margin	81.90%
EBIT Margin	81.40%
FCF Margin	53.43%

Dividends & Yields

This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.79%.

Dividend Per Share	1.50
Dividend Yield	0.79%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	23.99%
Buyback Yield	-7.66%
Shareholder Yield	-6.87%
Earnings Yield	3.72%
FCF Yield	2.05%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a